carnevalemanfredonia.it
» » COX-2: A New Target for Cancer Prevention and Treatment (Progress in Tumor Research, Vol. 37)

eBook COX-2: A New Target for Cancer Prevention and Treatment (Progress in Tumor Research, Vol. 37) download

by A.J. Dannenberg,R.N. DuBois,R.A. Stahel,S. Peters

eBook COX-2: A New Target for Cancer Prevention and Treatment (Progress in Tumor Research, Vol. 37) download ISBN: 380557536X
Author: A.J. Dannenberg,R.N. DuBois,R.A. Stahel,S. Peters
Publisher: S. Karger; 1 edition (May 2, 2003)
Language: English
Pages: 292
ePub: 1690 kb
Fb2: 1676 kb
Rating: 4.4
Other formats: mbr azw lit mobi
Category: Medics
Subcategory: Medicine

Cancer Prevention pp 37-47 Cite a. Suibbaramaiah K, Dannenberg AJ (2003) Caclooxygenase-2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24:96–102CrossRefGoogle Scholar.

Cancer Prevention pp 37-47 Cite as. Tumor Promotion as a Target of Cancer Prevention. Authors and affiliations. Tumor promotion is an essential process in multistage cancer development providing the conditions for clonal expansion and genetic instability of preneoplastic and premalignant cells.

Mobile version (beta). Epub FB2 mobi txt RTF. Converted file can differ from the original. If possible, download the file in its original format.

The cyclooxygenase-2 pathway as a target for treatment or prevention of cancer. June 2003 · Expert Opinion on Emerging Drugs

Fortschritte der experimentellen Tumorforschung. Progrès de la recherche expérimentale des tumeurs 37:107-23 · February 2003 with 4 Reads. Weak Cox-2 and moderate TBXAS expression was present in normal pituitary cells. Most pituitary adenomas showed increased expression of both Cox-2 and TBXAS. Pituitary tumors as a whole, but particularly carcinomas, showed greater Cox-2 expression than did normal pituitaries. The cyclooxygenase-2 pathway as a target for treatment or prevention of cancer. June 2003 · Expert Opinion on Emerging Drugs.

RESULTS: A total of 82 RCTs met inclusion criteria.

Joseph R. Bertino, Andrew J. Dannenberg, Raymond N. DuBois.

The first chapters are devoted to the epidemiology of nonsteroidal anti-inflammatory drugs (NSAIDs) and cancer, the pharmacology of COX-2 inhibitors and the regulation of COX-2 expression in human cancers. skin, breast, cervix, digestive tract, lung, et. Joseph R.

Cannabinoids in the Treatment of Cancer: Progress. Cancer is a disease characterized by uncontrolled division of cells and their ability to spread. This unregulated growth is caused by damage to DNA, resulting in mutations, defects in cell cycle, and apoptotic machinery. Thus, agents that can modulate apoptosis to maintain steady-state cell population by affecting one or more signaling intermediates leading to induction of apoptosis can be useful for targeted therapy of cancer. Hence, there is a need to develop novel targets and mechanism-based agents for the management of cancer.

This volume contains the majority of the invited keynote lectures presented by experts at the Third International Conference on Controversies in Tumor Prevention and Genetics on 12-14 February 2004 in S. allen, Switzerland

This volume contains the majority of the invited keynote lectures presented by experts at the Third International Conference on Controversies in Tumor Prevention and Genetics on 12-14 February 2004 in S. allen, Switzerland. Together, they reveal the latest findings in oncogenetics and its relations to recent and future developments in primary and secondary tumor prevention, especially in breast, colon and lung cancer.

Cyclooxygenase-2 (COX-2), an inducible prostaglandin synthase, is normally expressed in parts of the kidney and brain.

Aberrant COX-2 expression was first reported in colorectal carcinomas and adenomas, and has now been detected in various human cancers, including those of the breast. Strikingly, COX-2 overexpression in murine mammary gland is sufficient to cause tumour formation. To date, the role of COX-2 in tumorigenesis has been most intensively studied in the colon.

The combination of COX-2 inhibitors with radiation or other anti-cancer or cancer prevention drugs may reduce their side effects in future cancer prevention and treatment. Recent progress in the treatment and prevention of cancers of the colon, esophagus, lung, bladder, breast and prostate with NSAIDs, especially COX-2 inhibitors, is also discussed

COX-2: A New Target for Cancer Prevention and Treatment ed. by R. N. Dubois and A. J. Dannenberg Basel .

COX-2: A New Target for Cancer Prevention and Treatment ed. Dannenberg Basel ; New York : Karger, 2003. The role of COX-2 carcinogenesis by Andrew J Dannenberg; Raymond N Dubois; Steven M Dubinett; Nasser K Altorki; et al. Philadelphia, PA : Saunders, 2004.

Numerous investigators have found increased levels of cyclooxygenase-2 (COX-2) in both pre-malignant and malignant tissues. Moreover, animals engineered to be COX-2 deficient or treated with a selective COX-2 inhibitor showed reduced tumor formation and growth. The present book reviews these findings suggesting that COX-2 is a valid molecular target for the prevention and treatment of cancer. The first chapters are devoted to the epidemiology of nonsteroidal anti-inflammatory drugs (NSAIDs) and cancer, the pharmacology of COX-2 inhibitors and the regulation of COX-2 expression in human cancers. Besides, the book contains a series of chapters examining the link between COX-2 and cancer in specific organs (e.g. skin, breast, cervix, digestive tract, lung, etc.). Furthermore, several clinical trials assessing the potential of COX-2 inhibitors for preventing and treating cancer are described. The final chapter provides an up-to-date consideration of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. This state-of-the-art publication is recommended reading not only for medical and radiation oncologists, but also for pharmacologists, gastroenterologists and other subspecialists.